SIR2501, a SARM1 blocker with FDA Fast Track status for chemo nerve damage, gets three poster slots in Washington.

Employers get one platform for GLP-1 access, hormone therapy and chronic disease coaching, with clinicians still signing off ...

A new review argues that aging has several brakes, not one, and that the way genes are switched may hit the limit first.

A late-breaking slot in Boston will bring fresh data on an experimental drug that aims to turn down tau production in the ...

Ultrahuman’s racing partnership is about more than lap times; the bigger story is the teenage years when female healthspan takes shape.

RoC is recruiting at least 30 pairs of women 40 and older for a 12-week study that pairs skin checks with sleep and stress data.

A Frontiers in Aging perspective pitches encapsulated cells as a steady source of the antiaging protein, framed as a proposed ...

Alamar and Nightingale will hunt rare, low-level proteins in UK Biobank blood for signs of dementia and Parkinson’s long ...

Designerly’s Cooper Adwin on why regulatory governance and secure data architecture are critical for longevity biotech. Decentralized longevity trials put data infrastructure on the critical path to ...

Mission Therapeutics has begun a 36-patient Phase 1b study of MTX325, a drug aimed at clearing out damaged mitochondria in ...

Emory researchers say a 10-protein plasma signature outperformed the established marker, though it remains a research finding.

Why the next breakthroughs in healthy aging may come from the animal kingdom’s overlooked outliers, and from a rat with a genetic twist.